
Merck Gets EU CHMP Nod for KEYTRUDA® and Padcev® Combo in Urothelial Cancer
MSD, known as Merck outside the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy. This recommendation…











